Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Johnson and Johnson
McKinsey
Mallinckrodt
Dow

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Preladenant

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Preladenant?

Preladenant is an investigational drug.

There have been 13 clinical trials for Preladenant. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Parkinson Disease, Movement Disorders, and Dyskinesias. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Oregon Health and Science University, and [disabled in preview].

There are twenty-four US patents protecting this investigational drug and two hundred and sixty-three international patents.

Recent Clinical Trials for Preladenant
TitleSponsorPhase
Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)Merck Sharp & Dohme Corp.Phase 1
A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)Merck Sharp & Dohme Corp.Phase 1
A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)Merck Sharp & Dohme Corp.Phase 1

See all Preladenant clinical trials

Clinical Trial Summary for Preladenant

Top disease conditions for Preladenant
Top clinical trial sponsors for Preladenant

See all Preladenant clinical trials

US Patents for Preladenant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Preladenant   Start Trial Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Preladenant   Start Trial 1,2,4-triazine-4-amine derivatives Heptares Therapeutics Limited (Welwyn Garden, GB)   Start Trial
Preladenant   Start Trial Sustained release formulation and tablets prepared therefrom Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Preladenant   Start Trial Adenosine A2a receptor antagonists Schering Corporation (Kenilworth, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Preladenant

Drugname Country Document Number Estimated Expiration Related US Patent
Preladenant Australia 2013370977 2032-12-28   Start Trial
Preladenant Brazil 112015015468 2032-12-28   Start Trial
Preladenant Canada 2896056 2032-12-28   Start Trial
Preladenant China 105025899 2032-12-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
AstraZeneca
Baxter
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.